Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology

Journal of Immunotherapy

Volumn 33, Issue 2, 2010, Pages 219-224

  Märten, Angela ^a   Büchler, Markus W ^a   Werft, Wiebke ^b   Wente, Moritz N ^a   Kirschfink, Michael ^c   Schmidt, Jan ^a  

^a Department of Surgery ^*  (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Complement system pancreatic carcinoma; Diagnostic marker; IC3b

Indexed keywords

CA 19-9 ANTIGEN; CD59 ANTIGEN; CETUXIMAB; COMPLEMENT COMPONENT C3B; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIODIAGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR CELL; URINALYSIS;

ADENOCARCINOMA; AGED; CA-19-9 ANTIGEN; CELL LINE, TUMOR; COMPLEMENT C3B; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 77649150762     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181bed29f     Document Type: Article

References (31)

1. Raraty MG, Magee CJ, Ghaneh P, et al. New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol. 2002;41:582-595.
2. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344:1140-1144.
3. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058-1066.
4. Morgan BP. Regulation of the complement membrane attack pathway. Crit Rev Immunol.1999;19:173-198.
5. Ytting H, Jensenius JC, Christensen IJ, et al. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J Gastroenterol. 2004;39:674-679.
6. Ajona D, Castano Z, Garayoa M, et al. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res. 2004;64:6310-6318.
7. Gelderman KA, Hakulinen J, Hagenaars M, et al. Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model. Mol Immunol. 2003;40:13-23.
8. Baatrup G, Qvist N, Junker A, et al. Activity and activation of the complement system in patients being operated on for cancer of the colon. Eur J Surg. 1994;160:503-510.
9. Niculescu F, Rus HG, Retegan M, et al. Persistent complement activation on tumor cells in breast cancer. Am J Pathol. 1992;140:1039-1043.
10. Donin N, Jurianz K, Ziporen L, et al. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol. 2003;131:254-263.
11. Schmidt J, Klempp C, Buchler MW, et al. Release of iC3b from apoptotic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo. Cancer Immunol Immunother. 2006;55:31-38.
12. Sohn JH, Bora PS, Suk HJ, et al. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med. 2003;9:206-212.
13. Fyssas I, Syrigos KN, Konstantoulakis MM, et al. Thyroid autoantibodies and thyroid function in patients with pancreatic adenocarcinoma. Acta Oncologica (Stockholm, Sweden). 1997; 36:65-68. (Pubitemid 27135165)
14. Gansauge S, Gansauge F, Negri G, et al. The role of anti-p53- autoantibodies in pancreatic disorders. Int J Pancreatol. 1996;19:171-178.
15. Hamanaka Y, Suehiro Y, Fukui M, et al. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer. 2003;103:97-100.
16. Hong SH, Misek DE, Wang H, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res. 2004;64:5504-5510.
17. Maacke H, Hundertmark C, Miska S, et al. Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. J Cancer Res Clin Oncol. 2002;128:219-222.
18. Tomaino B, Cappello P, Capello M, et al. Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res. 2007;6:4025-4031.
19. Knaebel HP, Marten A, Schmidt J, et al. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma-CapRI: study protocol [ISRCTN62866759]. BMC Cancer. 2005;5:37.
20. Pepe MS, Longton G, Anderson GL, et al. Selecting differentially expressed genes from microarray experiments. Biometrics. 2003;59:133-142.
21. Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48:73-85.
22. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal. 2003;43: 121-137.
23. Raedle J, Oremek G, Welker M, et al. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas. 1996;13:241-246.
24. Kirschfink M. Targeting complement in therapy. Immunol Rev. 2001;180:177-189.
25. Fishelson Z, Donin N, Zell S, et al. Obstacles to cancer immuno-therapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol. 2003;40:109-123.
26. Kojima A, Iwata K, Seya T, et al. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol. 1993;151:1519-1527.
27. Ajona D, Hsu YF, Corrales L, et al. Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol. 2007;178:5991-5998.
28. Watson NF, Durrant LG, Madjd Z, et al. Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol Immunother. 2006;55:973-980.
29. Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225-1235.
30. Hanas JS, Hocker JR, Cheung JY, et al. Biomarker identification in human pancreatic cancer sera. Pancreas. 2008;36:61-69.
31. Macor P, Tripodo C, Zorzet S, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 2007;67:10556-10563